Brought to you by 
Boston Scientific licenses paclitaxel rights from Angiotech
31 Jul 2015
Executive Summary
Angiotech (inflammatory, angiogenesis-dependent diseases) has licensed Boston Scientific co-exclusive rights to use paclitaxel and related compounds as coatings for stents and devices to treat vascular and gastrointestinal diseases.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Medical Devices
- Implantable Devices
- Surgical Equipment & Devices
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Boston Scientific licenses paclitaxel rights from Angiotech
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice